Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:CASNumber |
123618-94-6
|
| gptkbp:developedBy |
gptkb:Yamanouchi_Pharmaceutical
|
| gptkbp:drugClass |
antiandrogen
steroidal antiandrogen |
| gptkbp:hasInChIKey |
QJQZQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasMolecularFormula |
C22H28N2O2
|
| gptkbp:hasSMILES |
CC#CC1(O)CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
|
| gptkbp:hasUNII |
6Q1K1Q1K1K
|
| https://www.w3.org/2000/01/rdf-schema#label |
YM905
|
| gptkbp:IUPACName |
(7α,17β)-17-hydroxy-7-methyl-17-(1-propynyl)androsta-4,6-dien-3-one
|
| gptkbp:mechanismOfAction |
androgen receptor antagonist
|
| gptkbp:molecularWeight |
352.47 g/mol
|
| gptkbp:PubChem_CID |
3083546
CHEMBL2105732 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
never marketed
|
| gptkbp:synonym |
YM-905
|
| gptkbp:therapeuticArea |
prostate cancer
|
| gptkbp:bfsParent |
gptkb:solifenacin
|
| gptkbp:bfsLayer |
7
|